TScan Therapeutics (TCRX) Other financing activities (2020 - 2025)
TScan Therapeutics (TCRX) posted quarterly Other financing activities of $9000.0 for Q4 2025, up 100.01% year-over-year from $4499.8 in Q4 2024, and up 200.0% quarter-over-quarter from -$9000.0 in Q3 2025.
TScan Therapeutics (TCRX) Other financing activities (2020 - 2025) Analysis & Trends
TScan Therapeutics (TCRX) has reported Other financing activities for 6 consecutive years, with $9000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 100.01% year-over-year to $9000.0; the TTM figure through Dec 2025 stood at $200000.0 (down 88.35% YoY), while the FY2025 annual figure was $200000.0, down 88.35% from the prior year.
- Other financing activities rose to $9000.0 in Q4 2025 per TCRX's latest filing, from -$9000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $127.8 million in Q3 2024 and bottomed at -$126.6 million in Q4 2024.
- Historically, Other financing activities has averaged -$5.0 million across 5 years, with a median of $65500.0 in 2021.
- Annual changes were most pronounced in 2023 — Other financing activities sank 132863.77% — and 2024, when it jumped 168297.37%.
- TScan Therapeutics' Other financing activities stood at $120000.0 in 2021, then sank by 42.5% to $69000.0 in 2022, then tumbled by 132863.77% to -$91.6 million in 2023, then plunged by 38.15% to -$126.6 million in 2024, then jumped by 100.01% to $9000.0 in 2025.
- Business Quant data shows TCRX's Other financing activities at $9000.0 in Q4 2025, -$9000.0 in Q3 2025, and $75000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Dec 31, 2024 | -126.56 Mn |
| Dec 31, 2024 | -126.56 Mn |
| Sep 30, 2024 | 127.83 Mn |
| Sep 30, 2024 | 127.83 Mn |
| Jun 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Mar 31, 2024 | 258,000.00 |
| Mar 31, 2024 | 258,000.00 |
| Dec 31, 2023 | -91.61 Mn |
| Dec 31, 2023 | -91.61 Mn |
| Sep 30, 2023 | -76,000.00 |
| Sep 30, 2023 | -76,000.00 |